ArticleJournal for immunotherapy of cancer2022

In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies.

Caterina Ieranò et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.